A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors.
- DOI
- 10.3390/cancers12061425
- Published
- 2020-05-31
- Container
- Cancers (Basel)
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3390/cancers12061425,
title = {A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors.},
author = {de Braud F and Machiels JH and Boggiani D and Rottey SWH and Duca M and Laruelle M and Salvagni S and Damian S and Lapeire LDF and Tiseo M and Dermine A and Ould-Kaci M and Braunger J and Rascher J and Fischer D and Hoefler J and Mariani GL and Cresta S.},
year = {2020},
journal = {Cancers (Basel)},
doi = {10.3390/cancers12061425},
url = {https://doi.org/10.3390/cancers12061425}
}RIS
TY - JOUR TI - A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors. AU - de Braud F AU - Machiels JH AU - Boggiani D AU - Rottey SWH AU - Duca M AU - Laruelle M AU - Salvagni S AU - Damian S AU - Lapeire LDF AU - Tiseo M AU - Dermine A AU - Ould-Kaci M AU - Braunger J AU - Rascher J AU - Fischer D AU - Hoefler J AU - Mariani GL AU - Cresta S. PY - 2020 JO - Cancers (Basel) DO - 10.3390/cancers12061425 UR - https://doi.org/10.3390/cancers12061425 ER -
APA
F, D. B., JH, M., D, B., SWH, R., M, D., M, L., S, S., S, D., LDF, L., M, T., A, D., M, O., J, B., J, R., D, F., J, H., GL, M., & S., C. (2020). A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors.. Cancers (Basel). https://doi.org/10.3390/cancers12061425
Source records
- europe-pmc · retrieved 2026-09-27T07:47:25.267Z